XLV trade ideas
XLV longNice looking ascending triangle, measured move target is 115. Looking like the channel may be the current trend for the next while.
XLVSame as the other defensive sectors posted, if healthcare cant hold 20, then 50/bottom of box is likely.
Healthcare might go this weekThe whole sector looks bullish. $HUM $UNH $ISRG all good setups as well
Health Care ETF Sneaks to New HighsThe SPDR Health Care ETF broke above its pre-Covid highs on July 17. Now it’s pulled back and is bouncing at those old levels. Is a stealth breakout taking place?
XLV has also formed a bullish ascending triangle, which it’s broken to the upside.
Health care is interesting because it lost more than 1 million workers amid the coronavirus lockdowns (according to Labor Department data). It’s not as bad as hotels or airlines, but it was clearly disrupted.
However unlike hotels and airlines, health care is a non-cyclical part of the economy that can still work during a recession. And recent numbers show it might be rebounding quickly. For example hospital operator HCA is up 35 percent in the last month, partially because admittances are rebounding. Equipment providers like Intuitive Surgical and Abiomed have also jumped as procedures resume.
Overall health-care isn’t the most exciting sector. But it is a big chunk of the economy. Like housing, it’s likely to recover much more quickly from the pandemic than other sectors. That may keep the buyers engaged, especially if XLV holds the recent low of $104.43.
XLV vs. SPX - Healthcare vs. S&P 500Relative strength from the Healthcare sector, coming off a failed breakdown in this relationship.
Let's Talk Market Consolidation Targets SPY QQQ XLF XLV June 10Pivoteering the market as we look to be on the verge of the first consolidation in a few weeks
SPDR Healthcare Sector XLV: Retest of $79 for buying opportunityVideos posted below! Have a great day
XLV prepare to Long, double bottom Existing condition:
1. Weekly demand zone confirmed
2. 15 min Chart double bottom formed
Buy 75.5 or better price
Stop: 73.5
Target 1: 81.5; risk:reward=1:3
Target 2: 86; risk:reward=1:5
This is a trading school homework. I need 6 months to practice trading plan.
If you like it, thank you for your support. Please use SIM/Demo account to try it, until my trading plans get high winning rate.
Sum of my ideas: 1 winner, 1 loser, 4 active, 8 cancelled, 4 pending for condition, 1 analysis only.
Healthcare probably going to take a hit this weekCongress's coronavirus stimulus deal reached Friday night included a provision requiring health insurers to bear the full cost of coronavirus test kits and to waive copays. The federal government will pay the cost for the uninsured. This will probably hurt health insurers Monday, though it might be good for service providers.
Here's another piece of bad news: xenophobia related to the virus has angered the Chinese government, and China’s official newspaper Xinhua published a threat to cut off supply chains for the US pharmaceutical industry. If China followed through on this threat, there could be big US drug shortages, which would be bad for pharmaceutical and healthcare companies.
The whole economy will be down this week due to expanding quarantines, new travel bans, and the failure of Trump's payroll tax cut proposal, but the healthcare sector may take extra damage Monday as it bears the brunt of the cost of coronavirus testing.
Staying short the XLV Caught between the 100 and 200day SMAXLV likely continues downward price action with Bernie continuing his strength towards the democratic convention. Just my opinion.
XLV
XLV breakout? Watch retest, quite possibly a fakeout.Healthcare is mirroring 2015-2016's triangle breakout pattern here with an obvious move above the trendline. LOTS of people see this, and there are many people viewing this as a repeat of the post 2015 rebound. I'm not totally sold on that scenario however. 2015-2016's healthcare consolidation saw a lot of frauds busted and companies deflated. Currently, we do not really have that environment to rebound from aside from the pharma companies who are going to be taking hits for opioid litigation, and we're facing some major political headwinds. While I can see some recovery from opioid settlements, I don't think we're past that as a risk quite yet, and we're coming to face other risks from the political process.
With that said, I DO like healthcare. It tends to be less cyclical than other sectors, and unlike utilities & reit's, this defensive sector isn't going to kill you if we see a return to inflation / reflation at any point.
Watch the breakout for a retest, and keep an eye on what it does. Markets love to fake people out, especially when everyone and their mother is seeing a repeat of previous patterns in play.
Healthcare Defensive at limitNote the pullbacks are always around Dec-Jan as well. Strong candidate for shorting here, and tends to come off fast.
Sell 104, SL 106.50, TP 96, RR 3.2.
XLV - DAILY CHARTHi, today we are going to talk about Health Care Select Sector SPDR Fund ETF and its current landscape.
The opioid crisis has been plaguing the U.S at the most for nearly two years now. With scary numbers like the record of 47,600* overdose deaths caused by opioids in 2017 but the number seems to start slowdown since 2018 were the war against opioids gained some traction.
In the justice field, some companies have already faced some sort of rebuke for involvement and even a bit of responsibility for the opioid crisis. For example
*Jun 2019, Insys Therapeutics Inc. had to file for bankruptcy after being convicted for conspiring to bribe doctors to increase opioid sales, ending up in a deal with the federal government of $225 million.
* Aug 2019, Johnson & Johnson was obligated to pay $572 Million, as Oklahoma ruled that the company intentionally played down the dangers and oversold the benefits of opioids.
* Oct 2019, Johnson & Johnson was once more condemned by two counties of Ohio to pay $20.4 million, with the accusation of having helped the opioid crisis to spread.
Now, that several healthcare companies are under investigation by the Federal Prosecutors in Brooklyn, into whether the company intentionally permitted that flood of opioids on the community. For now the U.S. Attorney’s Office in the Eastern District of New York it's just issuing subpoenas, but if they case sticks we might see what the murders of Julius Caesar saw, a pile of fire and anger from the people, so big that like Caesar butchers that were cast out of the city, the companies involved on this process can be drowned in liabilities and fines with the risk to be so badly damaged that may have the same fate of Insys Therapeutics Inc.and might hit this ETF that holds great exposure in the sector. The war against opioids it's just poised to grow up as every justice department across the country and every candidate that it's next to run on elections its eager to hang this trophy on the wall.
*Source: Centers for Disease Control and Prevention (CDC)
Thank you for reading and leave your comments if you like.
To have access to our exclusive contents, join the Traders Heaven today! Link Below.
Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
